Hidradenitis suppurativa biologic options widen past TNF
IL-17-class secukinumab and bimekizumab approvals plus emerging novel mechanism programs are restructuring hidradenitis suppurativa management.
Hidradenitis suppurativa has been a TNF-only category (adalimumab) for years. IL-17-class secukinumab and bimekizumab now carry HS approvals, and novel mechanism classes (IL-1 family targeting, complement, JAK pathway) are in late-stage trials. The diagnostic-pathway question is structural; HS is often misdiagnosed for years and prescribing patterns concentrate in dermatology specialty centres.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is lupus nephritis?
- SnapshotSjogren disease therapy reference (2026)
- ExplainedWhat is Sjogren disease?
- ExplainedWhat is ANCA-associated vasculitis?